Hemab Therapeutics names Keli Walbert to board, adds her to audit committee
Bitget2026/09/24 20:01- Hemab Therapeutics appointed Keli Walbert to its board, effective Sept. 24, 2026.
- Walbert will join the board’s Audit Committee, replacing Akshay Vaishnaw.
- Walbert most recently served as executive vice president of U.S. commercial at Horizon Therapeutics.
- Her background includes commercial leadership roles at AbbVie, the American Medical Association, Abbott, United Healthcare.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
